Skip to main content
SpringerLink
Log in

Optimal Use of Treprostinil in Pulmonary Arterial Hypertension

A Guide to the Correct Use of Different Formulations

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Treprostinil is a synthetic prostacyclin analogue with antiplatelet and vasodilatory properties. It is the only prostacyclin analogue with different options of delivery, i.e. subcutaneous, intravenous, inhaled or oral. Subcutaneous treprostinil has been shown in short- and long-term studies to improve exercise capacity, functional class, haemodynamics and survival in patients with pulmonary arterial hypertension (PAH). Pain at the infusion site has been a major drawback of subcutaneous treprostinil, hampering dose titration, and ultimately leading to increased discontinuation rates. The additional clinical interest in treprostinil as an alternative intravenous prostacyclin has developed due to its favourable properties, including longer half-life, chemical stability, the possibility of intravenous infusion without the need for ice packs, and easy drug preparation. Intravenous treprostinil improves exercise capacity, functional class and haemodynamics in patients with PAH, over the period of 12 weeks. If patients are switched to intravenous treprostinil, they usually need to double the dose to attain the same efficacy. Whether the effect of intravenous treprostinil remains clinically relevant beyond 12 weeks is not known, and a longer follow-up would be required to investigate this. Inhaled treprostinil is an efficacious treatment in PAH patients who are moderately symptomatic on background oral therapy. Oral treprostinil on top of background therapy did not lead to an improvement in 6-minute walking distance after 16 weeks of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70–5

    Article  PubMed  CAS  Google Scholar 

  2. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925–32

    Article  PubMed  CAS  Google Scholar 

  3. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008; 31: 891–901

    Article  PubMed  CAS  Google Scholar 

  4. Read NG, Radomski MW, Goodwin DA, et al. An ultrastructural study of stored human platelets after washing using prostacyclin. Br J Haematol 1985; 60: 305–14

    Article  PubMed  CAS  Google Scholar 

  5. Zardi EM, Zardi DM, Cacciapaglia F, et al. Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs. Int Immunopharmacol 2005; 5: 437–59

    Article  PubMed  CAS  Google Scholar 

  6. McNulty MJ, Sailstad JM, Steffen RP. The pharmacokinetics and pharmacodynamics of the prostacyclin analog 15au81 in the anesthetized beagle dog. Prostaglandins Leukot Essent Fatty Acids 1993; 48: 159–66

    Article  PubMed  CAS  Google Scholar 

  7. Remodulin™. Treprostinil sodium. Research Triangle Park (NC): United Therapeutics Corporation, 2002

    Google Scholar 

  8. Wade M, Hunt TL, Lai AA. Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. J Cardiovasc Pharmacol 2003; 41: 908–15

    Article  PubMed  CAS  Google Scholar 

  9. Wade M, Baker FJ, Roscigno R, et al. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. J Clin Pharmacol 2004; 44: 83–8

    Article  PubMed  CAS  Google Scholar 

  10. Laliberte K, Arneson C, Jeffs R, et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004; 44: 209–14

    Article  PubMed  CAS  Google Scholar 

  11. McSwain CS, Benza R, Shapiro S, et al. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. J Clin Pharmacol 2008; 48: 19–25

    Article  PubMed  CAS  Google Scholar 

  12. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003 Feb; 41(2): 293–9

    Article  PubMed  CAS  Google Scholar 

  13. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: 2362 a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800–4

    Article  PubMed  Google Scholar 

  14. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006; 28: 1195–203

    Article  PubMed  CAS  Google Scholar 

  15. Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006; 129: 1636–43

    Article  PubMed  CAS  Google Scholar 

  16. Sadushi-Kolici R, Skoro-Sajer N, Zimmer D, et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. J Heart Lung Transplant 2012; 31: 735–43

    Article  PubMed  Google Scholar 

  17. Skoro-Sajer N BD, Wiesbauer F, Harja E, et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension (cteph). J Thromb Haemost 2007 Mar; 5(3): 483–9

    Article  PubMed  CAS  Google Scholar 

  18. Mathier MA, McDevitt S, Saggar R. Subcutaneous treprostinil in pulmonary arterial hypertension: practical considerations. J Heart Lung Transplant 2010; 29: 1210–7

    Article  PubMed  Google Scholar 

  19. Skoro-Sajer N, Lang IM, Harja E, et al. A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension. Clin Pharmacokinet 2008; 47: 611–8

    Article  PubMed  CAS  Google Scholar 

  20. Hiremath J, Thanikachalam S, Parikh K, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant 2010; 29: 137–49

    Article  PubMed  Google Scholar 

  21. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006; 129: 683–8

    Article  PubMed  CAS  Google Scholar 

  22. Sakai T, Planinsic RM, Mathier MA, et al. Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end-stage liver disease. Transpl Int 2009; 22: 554–61

    Article  PubMed  CAS  Google Scholar 

  23. Saggar R, Shapiro SS, Ross DJ, et al. Treprostinil to reverse pulmonary hypertension associated with idiopathic pulmonary fibrosis as a bridge to single-lung transplantation. J Heart Lung Transplant 2009; 28: 964–7

    Article  PubMed  Google Scholar 

  24. Mclaughlin VV, Barst RJ, Gomberg-Maitland M, et al. One year experience with intravenous treprostinil in pulmonary arterial hypertension (PAH) patients [abstract]. Chest 2005 Oct; 128 (4 MeetingAbstracts): 160S–a–160S

    Google Scholar 

  25. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005; 172: 1586–9

    Article  PubMed  Google Scholar 

  26. Sitbon O, Manes A, Jais X, et al. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol 2007; 49: 1–5

    Article  PubMed  CAS  Google Scholar 

  27. Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol 2007; 99: 696–8

    Article  PubMed  CAS  Google Scholar 

  28. Centers for Disease Control and Prevention (CDC). Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension: seven sites, United States, 2003–2006. MMWR Morb Mortal Wkly Rep 2007 Mar 2; 56(8): 170–2

    Google Scholar 

  29. Kallen AJ, Lederman E, Balaji A, et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol 2008; 29: 342–9

    Article  PubMed  Google Scholar 

  30. Doran AK, Ivy DD, Barst RJ, et al. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 2008 Jul; (160): 5–9

    Google Scholar 

  31. O’Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections: the Hospital Infection Control Practices Advisory Committee, Center for Disease Control and Prevention, U.S. Pediatrics 2002 Nov; 110(5): e51

    Article  Google Scholar 

  32. Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006; 48: 1672–81

    Article  PubMed  CAS  Google Scholar 

  33. Channick RN, Olschewski H, Seeger W, et al. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol 2006; 48: 1433–7

    Article  PubMed  CAS  Google Scholar 

  34. Voswinckel R, Reichenberger F, Enke B, et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther 2008; 21: 824–32

    Article  PubMed  CAS  Google Scholar 

  35. Benza R, Rubin LJ, McLaughlin V, et al. Triumph 1: Long-term safety and efficacy of inhaled treprostinil sodium in patients with PAH. Two-year follow-up. Am J Respir Crit Care Med 2009; 179: A 1041

    Google Scholar 

  36. Bourge R, Tapson VF, Safdar Z, et al. Transitioning from inhaled iloprost to inhaled treprostinil sodium: an interim analysis. Am J Respir Crit Care Med 2010; 181: A3342

    Google Scholar 

  37. De Jesus Perez VA, Rosenzweig E, Rubin LJ, et al. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol 2012; 110: 1546–50

    Article  PubMed  Google Scholar 

  38. White RJ, Allen R, Torres F, et al. Sustained plasma concentrations of treprostinil following chronic dosing of oral treprostinil in patients with pulmonary arterial hypertension [poster]. American Thoracic Society International Conference; 2009 May 15–20; San Diego (CA)

  39. Gotzkowsky SK, Dingemanse J, Lai A, et al. Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. J Clin Pharmacol 2010; 50: 829–34

    Article  PubMed  CAS  Google Scholar 

  40. Rollins K, Peterson L, Laliberte K, et al. Overview of the drug-drug interaction potential with treprostinil [poster]. American Thoracic Society International Conference; 2009 May 15–20; San Diego (CA)

  41. Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. Epub 2012 May 24

  42. Roman A, Barbera JA, Escribano P, et al. Cost effectiveness of prostacyclins in pulmonary arterial hypertension. Appl Health Econ Health Policy 2012; 10(3): 175–88

    Article  PubMed  Google Scholar 

  43. Einarson TR, Granton JT, Vicente C, et al. Cost-effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: a Canadian analysis. Can Respir J 2005; 12: 419–25

    PubMed  CAS  Google Scholar 

  44. Narine L, Hague LK, Walker JH, et al. Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension. Curr Med Res Opin 2005; 21: 2007–16

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Internal Medicine II, Vienna General Hospital, Medical University of Vienna, Austria

    Nika Skoro-Sajer MD (Associate Professor)

Authors
  1. Nika Skoro-Sajer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nika Skoro-Sajer MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Skoro-Sajer, N. Optimal Use of Treprostinil in Pulmonary Arterial Hypertension. Drugs 72, 2351–2363 (2012). https://doi.org/10.2165/11638260-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11638260-000000000-00000

Keywords

Search

Navigation